We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+75.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$495M
AUM Growth
+$118M
Cap. Flow
-$4.08M
Cap. Flow %
-0.82%
Top 10 Hldgs %
52.26%
Holding
60
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$9.48M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.09M
4
OCUL icon
Ocular Therapeutix
OCUL
+$5.71M
5
CYTK icon
Cytokinetics
CYTK
+$5.68M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$36.8M
2
APTO
Aptose Biosciences, Inc.
APTO
+$6.39M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.83M
4
KALA icon
KALA BIO
KALA
+$4.76M
5
ZYME icon
Zymeworks
ZYME
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
26
DELISTED
Molecular Templates, Inc.
MTEM
$6.83M 1.38%
33,000
-2,560
-7% -$595K
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.55M 1.32%
238,300
+44,300
+23% +$1.21M
CMRX
28
DELISTED
Chimerix, Inc.
CMRX
$6.53M 1.32%
+2,105,000
New +$5.45M
LITS
29
Lite Strategy Inc
LITS
$34M
$6.43M 1.3%
+77,800
New +$4.72M
KYNB
30
Kyntra Bio
KYNB
$32.4M
$5.69M 1.15%
5,840
– –
KALV
31
DELISTED
KalVista Pharmaceuticals
KALV
$5.58M 1.13%
461,500
+236,500
+105% +$2.51M
CPRX
32
DELISTED
Catalyst Pharmaceutical
CPRX
$5.34M 1.08%
1,155,000
+105,000
+10% +$472K
BTAI icon
33
BioXcel Therapeutics
BTAI
$22.5M
$4.98M 1.01%
+5,875
New +$3.83M
FOCL
34
EDAP TMS S.A.
FOCL
$199M
$4.65M 0.94%
1,878,500
-315,000
-14% -$756K
KALA icon
35
KALA BIO
KALA
$15.7M
$3.79M 0.77%
145
-168
-54% -$4.76M
CDTX
36
DELISTED
Cidara Therapeutics
CDTX
$3.58M 0.72%
48,533
+3,230
+7% +$209K
LQDA icon
37
Liquidia Corp
LQDA
$6.26B
$3.37M 0.68%
+400,000
New +$3.04M
ARDX icon
38
Ardelyx
ARDX
$986M
$3.26M 0.66%
+471,600
New +$3.28M
TELA icon
39
TELA Bio
TELA
$29.2M
$3.24M 0.65%
250,000
+169,000
+209% +$2.22M
AMRN
40
Amarin Corp
AMRN
$297M
$3.15M 0.64%
22,750
– –
CRDF icon
41
Cardiff Oncology
CRDF
$76.7M
$2.96M 0.6%
+590,000
New +$1.21M
ADMS
42
DELISTED
Adamas Pharmaceuticals
ADMS
$2.46M 0.5%
+960,000
New +$2.82M
FENC icon
43
Fennec Pharmaceuticals
FENC
$413M
$1.43M 0.29%
+171,000
New +$1.27M
EPIX
44
DELISTED
ESSA Pharma
EPIX
$1.08M 0.22%
+175,000
New +$830K
AUTL
45
Autolus Therapeutics
AUTL
$628M
$962K 0.19%
+60,000
New +$665K
ASRT
46
DELISTED
Assertio
ASRT
$754K 0.15%
+14,667
New +$756K
DNTH icon
47
Dianthus Therapeutics
DNTH
$6.24B
$385K 0.08%
3,202
-23,968
-88% -$3.38M
BLRX
48
BioLineRX
BLRX
$12.1M
$29K 0.01%
417
– –
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$5.12B
– –
-1,500
Closed -$63K
NERV icon
50
Minerva Neurosciences
NERV
$245M
– –
-56,263
Closed -$2.71M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2020 Portfolio in Review

As of Q2 2020, Opaleye Management held 60 positions worth $495M, up 31% from $377M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opaleye Management's Q2 2020 filing shows 16 new, 13 increased, 8 reduced and 12 closed positions. Its largest new stake was Fortress Biotech: 255,333 shares worth $10.3M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Opaleye Management's largest Q2 2020 buy was Fortress Biotech: 255,333 shares worth $10.3M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2020, an estimated $5.71M increase.
  • Opaleye Management's biggest Q2 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $6.39M.
  • Opaleye Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $36.8M.
  • Opaleye Management's ten largest holdings make up 52% of its $495M portfolio in Q2 2020.
  • Opaleye Management opened 16 new positions and closed 12 in Q2 2020.
  • Opaleye Management's portfolio value rose 31% quarter-over-quarter to $495M.

Based on Opaleye Management's 13F filing for Q2 2020, filed 14 Aug 2020.